Related Experiment Videos
Potential test systems for drugs against prostatic cancer
Cancer Chemotherapy Reports
|January 1, 1975
Summary
Researchers evaluated two model systems for prostate cancer drug discovery. These models assessed chemotherapeutic effects on rat prostate enzymes and hormone deposition in dogs, identifying potential indicators for effective prostate cancer treatments.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Prostate cancer treatment requires effective chemotherapeutic agents.
- Androgen-dependent enzymes like 5 alpha-reductase and arginase are crucial for prostate function.
- Developing reliable preclinical models is essential for identifying promising drug candidates.
Purpose of the Study:
- To evaluate two novel model systems for screening chemotherapeutic agents against prostate cancer.
- To assess the impact of various drugs on rat prostatic enzyme activities (5 alpha-reductase and arginase).
- To investigate the effect of drug therapy on hormone (estriol and testosterone) deposition in the canine prostate.
Main Methods:
- Assessed the effects of chemotherapeutic agents on rat prostatic 5 alpha-reductase and arginase activities using Lineweaver-Burk plots to determine Michaelis constants.
- Investigated the deposition of labeled estriol and testosterone in the dog prostate under drug therapy.
- Compared drug-induced enzyme inhibition and hormone deposition patterns against control groups.
Main Results:
- Several agents, including isophosphamide, bleomycin, and procarbazine, inhibited rat prostatic 5 alpha-reductase.
- 5-fluorouracil, vincristine, bleomycin, procarbazine, adriamycin, and hexamethyl-melamine significantly inhibited arginase activity.
- Streptozotocin and NSC-45388 inhibited arginase in the ventral gland only, while some drugs showed competitive inhibition in the dorsolateral gland.
- Seven drugs activated 5 alpha-reductase, and streptozotocin and procarbazine interfered with estriol and testosterone deposition in dogs.
Conclusions:
- The evaluated rat prostatic enzyme and canine prostate hormone deposition models show promise as reliable indicators for drug efficacy in prostate cancer.
- These preclinical models can aid in the selection of chemotherapeutic agents for clinical trials in prostate cancer patients.
- Understanding drug interactions with androgen-dependent pathways is key to developing targeted prostate cancer therapies.